Effect of Insulin and Insulin Pulses on Fasting Glucagon Secretion and on Glucose Metabolism in Subjects Without Type 2 Diabetes
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Mayo Clinic
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Suppression of Endogenous glucose production (EGP) by insulin
Study Overview
Brief Summary
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
Detailed Description
Decreased insulin action increases glucagon concentrations. In rodents, insulin signaling restrains glucagon secretion. It is unclear if this is the case in all (subtypes of) prediabetes. Impaired hepatic insulin action exacerbates glucagon's effects on endogenous glucose production. Also, insulin resistance in the β-cell impairs negative feedback inhibition of insulin secretion. This leads to hyperinsulinemia in rodents and humans. How these variables interact is unknown. This experiment will determine how insulin variably regulates fasting glucagon (and insulin) secretion directly, or indirectly, in prediabetes.
The inability of the proinsulin to insulin ratio to reliably predict β-cell integrity, endoplasmic reticulum stress and β-cell function has led to the identification of novel markers of β-cell health. In addition, the relationship of glucagon and insulin pulses will be quantified. Preliminary data shows that there is heterogeneity in these relationships even in normal fasting glucose. Th experiment will also determine how islet hormone / glucose crosstalk and pulse characteristics contribute to prediabetes.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 25 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •people with normal or impaired fasting glucose and normal or impaired glucose tolerance
Exclusion Criteria
- •HbA1c > 6.5%
- •BMI ≥ 35 Kg/M2
- •Use of any glucose-lowering agents including metformin or sulfonylureas.
- •For female subjects: positive pregnancy test at the time of enrollment or study
- •History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- •Active systemic illness or malignancy.
- •Symptomatic macrovascular or microvascular disease.
- •Hematocrit < 35%
Arms & Interventions
Intralipid and heparin
Between 0600 (-180 min) and 1300 (240 min) Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance.
Intervention: Intralipid and heparin (Other)
Saline
Between 0600 (-180 min) and 1300 (240 min) saline will be infused
Intervention: Saline (Other)
Outcomes
Primary Outcomes
Suppression of Endogenous glucose production (EGP) by insulin
Time Frame: The rate of EGP at 240 minutes (end of study) expressed as a percentage of fasting EGP (at the start of the study i.e.: 0 minutes.
comparison of EGP in people with IFG vs NFG in response to insulin infusion
Insulin pulse orderliness
Time Frame: Approximate Entropy (ApEn) will be calculated from the insulin concentrations observed every 2 minutes between -45 and 0 minutes
comparison of Insulin pulse orderliness measured by approximate entropy in people with IFG vs NFG
Secondary Outcomes
No secondary outcomes reported
Investigators
Adrian Vella
Professor of Medicine
Mayo Clinic